Literature DB >> 15636586

Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.

Gilles Ferry1, Caroline Ubeaud, Pierre-Hervé Lambert, Sophie Bertin, Francis Cogé, Pascale Chomarat, Philippe Delagrange, Bernard Serkiz, Jean-Paul Bouchet, Roger J W Truscott, Jean A Boutin.   

Abstract

The catabolism of melatonin, whether naturally occurring or ingested, takes place via two pathways: approximately 70% can be accounted for by conjugation (sulpho- and glucurono-conjugation), and approximately 30% by oxidation. It is commonly thought that the interferon-induced enzyme indoleamine 2,3-dioxygenase (EC 1.13.11.42), which oxidizes tryptophan, is also responsible for the oxidation of 5-hydroxytryptamine (serotonin) and its derivative, melatonin. Using the recombinant enzyme expressed in Escherichia coli, we show in the present work that indoleamine 2,3-dioxygenase indeed cleaves tryptophan; however, under the same conditions, it is incapable of cleaving the two other indoleamines. By contrast, myeloperoxidase (EC 1.11.1.7) is capable of cleaving the indole moiety of melatonin. However, when using the peroxidase conditions of assay -- with H2O2 as co-substrate -- indoleamine 2,3-dioxygenase is able to cleave melatonin into its main metabolite, a kynurenine derivative. The present work establishes that the oxidative metabolism of melatonin is due, in the presence of H2O2, to the activities of both myeloperoxidase and indoleamine 2,3-dioxygenase (with lower potency), since both enzymes have Km values for melatonin in the micromolar range. Under these conditions, several indolic compounds can be cleaved by both enzymes, such as tryptamine and 5-hydroxytryptamine. Furthermore, melatonin metabolism results in a kynurenine derivative, the pharmacological action of which remains to be studied, and could amplify the mechanisms of action of melatonin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15636586      PMCID: PMC1186709          DOI: 10.1042/BJ20042075

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Oxidation of melatonin and tryptophan by an HRP cycle involving compound III.

Authors:  V F Ximenes; L H Catalani; A Campa
Journal:  Biochem Biophys Res Commun       Date:  2001-09-14       Impact factor: 3.575

2.  Expression and purification of recombinant human indoleamine 2, 3-dioxygenase.

Authors:  T K Littlejohn; O Takikawa; D Skylas; J F Jamie; M J Walker; R J Truscott
Journal:  Protein Expr Purif       Date:  2000-06       Impact factor: 1.650

3.  The fate of melatonin in animals.

Authors:  I J KOPIN; C M PARE; J AXELROD; H WEISSBACH
Journal:  J Biol Chem       Date:  1961-11       Impact factor: 5.157

Review 4.  Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.

Authors:  T W Stone
Journal:  Prog Neurobiol       Date:  2001-06       Impact factor: 11.685

5.  Mechanism of reaction of melatonin with human myeloperoxidase.

Authors:  M Allegra; P G Furtmüller; G Regelsberger; M L Turco-Liveri; L Tesoriere; M Perretti; M A Livrea; C Obinger
Journal:  Biochem Biophys Res Commun       Date:  2001-03-30       Impact factor: 3.575

6.  Identification of highly elevated levels of melatonin in bone marrow: its origin and significance.

Authors:  D X Tan; L C Manchester; R J Reiter; W B Qi; M Zhang; S T Weintraub; J Cabrera; R M Sainz; J C Mayo
Journal:  Biochim Biophys Acta       Date:  1999-10-18

7.  Myeloperoxidase-catalyzed oxidation of melatonin by activated neutrophils.

Authors:  S O Silva; V F Ximenes; L H Catalani; A Campa
Journal:  Biochem Biophys Res Commun       Date:  2000-12-20       Impact factor: 3.575

8.  N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant.

Authors:  D X Tan; L C Manchester; S Burkhardt; R M Sainz; J C Mayo; R Kohen; E Shohami; Y S Huo; R Hardeland; R J Reiter
Journal:  FASEB J       Date:  2001-08-17       Impact factor: 5.191

9.  Identification of the melatonin-binding site MT3 as the quinone reductase 2.

Authors:  O Nosjean; M Ferro; F Coge; P Beauverger; J M Henlin; F Lefoulon; J L Fauchere; P Delagrange; E Canet; J A Boutin
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

10.  Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .

Authors:  O Nosjean; J P Nicolas; F Klupsch; P Delagrange; E Canet; J A Boutin
Journal:  Biochem Pharmacol       Date:  2001-06-01       Impact factor: 5.858

View more
  18 in total

1.  Evaluation of melatonin and AFMK levels in women with breast cancer.

Authors:  Tialfi Bergamin de Castro; Newton Antônio Bordin-Junior; Eduardo Alves de Almeida; Debora Aparecida Pires de Campos Zuccari
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

2.  Melatonin ameliorates oxidative stress and induces cellular proliferation of lymphoid tissues of a tropical rodent, Funambulus pennanti, during reproductively active phase.

Authors:  Rai Seema; Haldar Chandana
Journal:  Protoplasma       Date:  2011-12-29       Impact factor: 3.356

Review 3.  Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance.

Authors:  Rüdiger Hardeland
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

4.  Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice.

Authors:  Sida Niu; Feng Li; Dun-Xian Tan; Lirong Zhang; Jeffrey R Idle; Frank J Gonzalez; Xiaochao Ma
Journal:  J Pineal Res       Date:  2010-05-27       Impact factor: 13.007

5.  A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites.

Authors:  Luisa Rios-Avila; H Frederik Nijhout; Michael C Reed; Harry S Sitren; Jesse F Gregory
Journal:  J Nutr       Date:  2013-07-31       Impact factor: 4.798

6.  Indole peroxygenase activity of indoleamine 2,3-dioxygenase.

Authors:  Hsin H Kuo; A Grant Mauk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

7.  Ferryl derivatives of human indoleamine 2,3-dioxygenase.

Authors:  Changyuan Lu; Syun-Ru Yeh
Journal:  J Biol Chem       Date:  2011-04-18       Impact factor: 5.157

8.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 9.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

10.  Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide.

Authors:  Mohammed Freewan; Martin D Rees; Tito S Sempértegui Plaza; Elias Glaros; Yean J Lim; Xiao Suo Wang; Amanda W S Yeung; Paul K Witting; Andrew C Terentis; Shane R Thomas
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.